Board Decision on Animal Patents Sparks Debate

WASHINGTON—A U.S. patent board ruling last month significantly boosts the odds for approval of some of the pending applications for patents on genetically engineered animals. The U.S. Patent and Trademark Office's Board of Patent Appeals and Interferences, while rejecting for other reasons an application for a patent on an oyster, ruled that there is no legal reason why such patent protection should be denied. The decision may lead eventually to the marketing of new breeds of faster-growin

Written byStephen Greene
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The U.S. Patent and Trademark Office's Board of Patent Appeals and Interferences, while rejecting for other reasons an application for a patent on an oyster, ruled that there is no legal reason why such patent protection should be denied.

The decision may lead eventually to the marketing of new breeds of faster-growing poultry or leaner livestock, for example, and to laboratory animals susceptible to human diseases or otherwise tailored for research. Meanwhile, its moral and ethical implications are sure to spark heated debate.

U.S. patent protection was limited to inanimate objects until 1980, when the Supreme Court ruled in Diamond v. Chakrabarty that genetically altered bacteria developed by microbiologist Ananda Chakrabarty fell within the scope of patent law. In 1985 the Board of Patent Appeals decided that plants, granted similar protection under separate statute, also were patentable. But patent examiners have continued to reject applications for animal patents.

In its ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies